DAFTAR PUSTAKA
1. Cappelini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A, : Thalassemia International Federation; 2008, 2nd
2. Weatherall, DJ. The Thalassemias. Williams hematology. 6th edition. Mc-Graw Hill,November 2000.2
ed. Cyprus, 2010
3. Weatherall, DJ, Clegg Jb. Thalassemia Syndromes. 4rd edition.Blackwell science.UK.2001
4. Pignatti CB, Galanello R.Thalassemias and Related disorders: Quantitative Disorderd of Hemoglobin Synthesis. In: Wintrobe’s Clinical Hematology. Lipincot Williams & Wilkins. Philadelphia.2009;C 39:p.1084-1130
5. Cavalli-Sforza, L.L.,Menozzi, P . and Piazza A.1994. The History and Geography of Human Genes. Princeton University Press.
Princeton, New Jersey. 2: 60-121
6. I Wahidiyat, PA Wahidiyat. Genetic problems at present and their challenges in future: Thalassemia as a model [serial online] 2006 [cited 2010 Nov 22] Available from: Pediatrica Indonesia
8. Langlois S, Ford JC, Chitayat D. Carrier Screening for Thalassemia and Hemoglobinopathies in canada. Joint SOGC-CCMG Clinical Practice Guidline 2008, 218: 950-959
9. Lanni F. Heterogenitas molekular Genaglobin-β di Indonesia, kaitannya dengan pola penyebaran thalassemia-β serta afinitas genetik antar populasi di Indonesia [Disertasi Doktor bidang Ilmu Kedokteran Universitas Gajah Mada]. Yogyakarta: Universitas Gajah Mada; 2002.
10. World Health Organization/Thalassemia International Federation. Prosiding dari: Joint meeting on the prevention and control of haemoglobinopathies. Nicosia-cyprus: World Health Organization/Thalassemia International Federation, 1994:20
11. Eleftheriou A. What is the thalassemia. Thalassaemia International Federation. Nicosia-Cyprus, 2003.
12. Taher A, Vichnsky E, Musallam K, Domenica M, Cappellini, Viprakasit V, Guideline For The Management Of Non Transfusion Dependent Thalassemia (NTDT)
13. Nemeth E. Hepcidin in Β Thalassemia [serial online]. 2010 [ cited 2010 Jul 23] . Available from : Gene Review.
14. Nemeth, E Targetting the Hepcidin-Ferroportin Axis in the Diagnosis and Treatment of Anemias 2010. Advances in Hemtology
15. Zimmermann M.B, dkk. Iron metabolism in heterozygotes for
coumpound heterozygotes for HbE/b-thalassemia. American Journal of
Clinical Nutrition
16. Galanello R and Origa R. Beta-Thalassemia. Orphanet Journal Of Rare Diseases 2010.
17. Kattamis A,dkk. The effects of rytropoetic activity and iron burden on hepcidin expression in patients with thalassemia major.2006 [cited 2011 agt 3].
18. Rachmilewitz EA, and Giardina PJ. How I Treat Thalassemia, in:How I Treat. Blood, 2011;3479-3488.
19. Collins, F.S. and Weissman, S.M. 1984. “The Molecular Genetics of Human Hemoglobin “ .Prog. Nucleic Acid Res. Mol.Biol. 31:315
20. Galanello R and Origa R. Beta-Thalassemia. Orphanet Journal Of Rare Diseases 2010.
21. Srivorakun H, Fucharoen G, Changtrakul Y, Komwilaisak P, n Fucharoen S. Thalassemia and hemoglobinopathies in Southeast
22. Wirawan R. Analisa Hemoglobin dengan cara konvensional dan mikrokapiler elektroforesis. Jakarta. Balai Penerbit FKUI, 2011;h.78. 23. Bain BJ. Haemoglobin and the genetic of haemoglobin synthesis, in:
Haemoglobinopathy. Second Edition. Blackwell Publishing. 2006;p.1-25
Hemoglobin. Genetics, Pathophysiology, and Clinical. Cambridge University Press. New York. 2009;p.46-61
25. About Alpha Thalassemia. In: Hemoglobin Disorders Hemoglobinopathies. Thalassemia International Federation. 2007.
26. Ghodekar SR, Gramurohit ND, Kadam SS, and Thorat RM. Thalassemia: A Review. International Journal of Pharma research and Development-Online (IJPRD).2010.
27. Dimitris L,Leukopoulos. Haemoglobinophaties. Macmillan Plubisher Ltd. 2002.
28. Weatherall DJ. Fortnightly review: The Thalassemia. BMJ, 1977; Ltd.2002
29. Dessypris EN, Sawyer ST. Erythropoiesis. In: Wintrobes’s Clinical Hematology, 12nd
30. Wickrema A, Kee B. Molecular Basis of Hematopoiesis. Springer Science New York 2009 : 74
ed. Lippincot Williams & Wilkins Philadelphia 2009: 107
31. Andrews NC. Iron Deficiency and Relared Disorders. In : Wintrobe’s Clinical Hematology, 12nd
32. Hoffbrand AV, Catovsky D, Tuddenham EGD. Postgraduate Hematology 5
ed. Lippincot Williams & Wilkins Philadelphia 2009 : 815
th ed. Blackwell Publishing Ltd Massachusetts 2005 :
33. Srivorakun H, Fucharoen G, Changtrakul Y, Komwilaisak P, n Fucharoen S. Thalassemia and hemoglobinopathies in Southeast Asian newborns: diagnostic assessment using capillary electrophoresis system. Clinical Biochemistry. Published by Elsevier Inc. 2011; 406-411.
34. John M,Old. DNA Diagnosis of Hemoglobin Mutations. In:Hemoglobin Disorde Molecular and Protocols. Humana Press Inc. Totowa,NJ,2003,Vol 82; 101-108.
35. Elizabeth G. Genotype-phenotype Diversity of Beta-Thalassemia in malaysia: Treatment Options and Emerging Therapies.
36. Bain BJ. The α, β, δ dan γ Thalassaemias and related conditions, in: Hemoglobinopathy. Second Edition. Blackwell Publishing.2006;p:63-138
37. Rozenberg G. Haemoglobin Disrorders, in: Microscopic 3e Haematology a Practical Guide for The Laboratory. Elsevier. Australia. 2011;p:23-33
38. Rund D and Rachmilewitz E. Β-thalassemia. N ENGL J MED, 353;11 39. Chui DH, Cunningham MJ, Lou Hy, Wolf LC, Neufeld EJ, and
Steinberg MH. Screening and counseling for Thalassemia. Blood 2006;vol 107.Number 4
41. Eleftheriou A. What is the thalassemia . Thalassemia International Federation. Nicosia-Crprus, 2003
42. Pignatti CB, Galanello R. Thalassemia and related disorders: quantitative disorders of hemoglobin synthesis. Dalam: Greer JP, Foerster J, Rodgers GM, et al., editors. Wintrobe’s clinical hematology. 12nd
43. Mosca A, Paleari R, Ivaldi G, Galanello R, dan Giordano PC. The role of haemoglobin A2 testing in the diagnosis of thalassaemias and related haemoglobinopathies. J Clin Pathol 2009;62:13–17.
ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p.1083-1098
44. Mais DD, Gulbranson RD, and Keren DF. The Range of Hemoglobin A2 in hemoglobin E Heterozygotes as Determined by Capillary Electrophoresis. Am J Clin Pathol 2009;132:34-38.
45. Pardede, D.K.B.2013. Hepcidin : Perannya dalam pathogenesis dan implikasinya terhadap tatalaksana anemia pada penyakit kronis.
46. Krause, A., S. Neitz, H.J.Magert. et al, 2000. LEAP-1 , a novel highly disulfide – bonded human peptide, exhibits antimicrobial activity, FEBS Lett, 480:147-150
47. Ganz, T.2003. Hepcidin , a key regulator of iron metabolism and mediator of anemia of inflammation. Blood, 20014
48. Perdana Y W, Jacobus J D. Hepcidin dan Anemia Defisiensi Besi
50. Testa U. Protein of Iron metabolism. Florida: CRC Press; 2002. p.143-382.
51. Biovendor Research and Diagnostic product. Version 57 030412 15 52. Worwood M, May A. Iron Deficiency Anemia and Iron Overload. In
Dacie & Lewis Practical Hematology 11th
53. Atmakusuma D. Thalassemia: Manifestasi Klinis , Pendekatan diagnosis, dan Thalassemia Intermedia. Dalam: Ilmu Penyakit Dalam. Internal Publishing. Jilid II, Edisi V, Bab 220; 1387-1405.
ed. Elsevier Churchill Livingstone 2011:190
54. Fucharoen S, Winichagoon P.in: New updating into hemoglobinopathies. International Journal of laboratory Hematology. Blackwell Publishing Ltd. 2012:559-565.
55. Giordano PC. Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: interpretation of results and pitfalls. International Journal of laboratory Hematology. Blackwell Publishing Ltd. 2012; 1-15.
56. Macdougall, I.C., J. Malyazko, R.C.Hider, and S.S. Bansal. 2010. Current Status of theMeasurement of Blodd Hepcidin level in Chronic Kidney Disease. Clin J Am Soc neprol, 5: 1681-1689
57. Bain.J.B, Bates.I, Laffan.A.M, Lewis.S.M, Dacie and Lewis Practical Haematology: Eleventh Edition181-190
